Sanofi Pasteur, the vaccination division of French pharmaceutical giant Sanofi, is starting its phase 3 clinical trials for a COVID-19 vaccine in partnership with the British group GSK in Colombia.
It is a recombinant protein vaccine whose study will be carried out in seven research centers in Bogotá, Barranquilla, Cali, Florida Blanca, Soledad, Chía, and Girardot.
More than 35,000 volunteers over 18 years of age from different countries in Asia, Africa, Latin America, and North America will participate in the study.
Two weeks ago, Brazil’s health regulator Anvisa approved the company’s request to carry out phase 1 and phase 2 clinical trials for its COVID-19 vaccine in the country as well.
The shot will use mRNA technology, the same one of Pfizer‘s and Moderna‘s COVID-19 jabs.